Patient characteristics
| Characteristic . | No. (%) . |
|---|---|
| Age at transplantation, y | |
| Median (range) | 55.2 (12.2-68.4) |
| < 50 | 11 (33) |
| ≥ 50 | 22 (67) |
| Sex | |
| Male | 14 (42) |
| Female | 19 (58) |
| Diagnosis/disease status | |
| NHL | |
| 1RL | 2 (6) |
| 2RL | 1 (3) |
| IF | 1 (3) |
| MM | |
| PR | 2 (6) |
| PD | 1 (3) |
| CMML | 1 (3) |
| ALL | |
| 1CR | 2 (6) |
| 2CR | 1 (3) |
| AML | |
| 1CR | 7 (21) |
| 2CR | 2 (6) |
| 1RL | 3 (0) |
| 3RL | 1 (3) |
| IF | 6 (18) |
| CML | |
| 2CP | 1 (3) |
| CMLt | 1 (3) |
| MDS | |
| RARS | 1 (3) |
| Prior BMT | |
| Auto | 1 (3) |
| MUD | 2 (6) |
| Race | |
| White | 29 (88) |
| Black | 3 (9) |
| Asian | 1 (3) |
| Donor type | |
| Matched related | 13 (39) |
| Mismatched related | 3 (9) |
| Matched unrelated | 15 (46) |
| Mismatched unrelated | 2 (6) |
| Characteristic . | No. (%) . |
|---|---|
| Age at transplantation, y | |
| Median (range) | 55.2 (12.2-68.4) |
| < 50 | 11 (33) |
| ≥ 50 | 22 (67) |
| Sex | |
| Male | 14 (42) |
| Female | 19 (58) |
| Diagnosis/disease status | |
| NHL | |
| 1RL | 2 (6) |
| 2RL | 1 (3) |
| IF | 1 (3) |
| MM | |
| PR | 2 (6) |
| PD | 1 (3) |
| CMML | 1 (3) |
| ALL | |
| 1CR | 2 (6) |
| 2CR | 1 (3) |
| AML | |
| 1CR | 7 (21) |
| 2CR | 2 (6) |
| 1RL | 3 (0) |
| 3RL | 1 (3) |
| IF | 6 (18) |
| CML | |
| 2CP | 1 (3) |
| CMLt | 1 (3) |
| MDS | |
| RARS | 1 (3) |
| Prior BMT | |
| Auto | 1 (3) |
| MUD | 2 (6) |
| Race | |
| White | 29 (88) |
| Black | 3 (9) |
| Asian | 1 (3) |
| Donor type | |
| Matched related | 13 (39) |
| Mismatched related | 3 (9) |
| Matched unrelated | 15 (46) |
| Mismatched unrelated | 2 (6) |
NHL indicates non-Hodgkin lymphoma; MM, multiple myeloma; CMML, chronic myelomonocytic leukemia; ALL, acute lymphoblastic leukemia; AML, acute myelogenous leukemia; CML, chronic myelogenous leukemia; CMLt, CML in transformation; MDS, myelodysplastic syndrome; Auto, autologous; MUD, matched unrelated donor; CR, complete remission; CP, chronic phase; IF, induction failure; PD, progressive disease; PR, partial response; and RARS, refractory anemia with ring sideroblasts.